- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04931121
EVALUATION OF THE CAPACITY OF A BIOMARKER BASED ON THE RAMAN ANALYSIS OF SYNOVIAL FLUID (VISCODIAG)
EVALUATION OF THE CAPACITY OF A BIOMARKER BASED ON THE RAMAN ANALYSIS OF SYNOVIAL FLUID TO IDENTIFY ARTHROSIC PATIENTS RESPONDING TO VISCOSUPPLEMENTATION / VISCODIAG
Osteoarthritis (OA) is the most common joint disease in the world and induces major physical, psychological, societal and economic burdens.
The management of osteoarthritis is complex. Viscosupplementation by local injection in the arthritic knee is a validated therapy used after failure of conventional analgesic treatments and non-pharmacological modalities. The size effect of this treatment is modest between 0.3 and 0.6. We do not currently have any predictive criteria for the effectiveness of this treatment.
The procedure tested in this research is the characterization of synovial fluid (SF) by an in vitro Raman microspectroscopy technique.
The results obtained will make it possible to compare the effectiveness of visco-supplementation with hyaluronic acid from the Hyalgan© trade according to classic criteria in the literature.
Study Overview
Detailed Description
The proposed study consists in analysing the synovial fluid (SF) of patients obtained in conventional care that do not require new medical or nursing procedures.
All care that patients will receive is routinely provided by physicians. There is no additional act of surveillance during the research. The follow-up medical visits are exactly the same as those offered to patients as part of their treatment, no additional visits are required.
During the orthopedic consultation for HA injection, the initial WOMAC score as well as the PGAP and PASS scores will be measured. SF, usually considered as medical waste, will be collected during an arthrocentesis prior to the intra-articular injection of hyaluronic acid, freezed at -80°C and then sended to the IVTV platform at the Ecole Centrale de Lyon for DDRS Raman spectroscopy (LabRam HR 800, Horiba Jobin Yvon, Villeneuve d'Asq). Studied SYNODIAG biomarkers are dried drops parameters (surface) and Raman ratios according to the FR3059781 patent.
At the 6-month follow-up visit, WOMAC, PGAP and PASS scores will be re-measured to determine the patient's responding/non-responding status.
Finally, the objective of the study is to verify if there are significant differences between the Raman ratios and dried drops parameters of SF patients responding and non-responding to viscosupplementation.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: GRANGE Laurent
- Phone Number: +33 (0)4 76 76 51 36
- Email: lgrange@chu-grenoble.fr
Study Contact Backup
- Name: GRUEL Réjane
- Phone Number: +33 (0)4 76 76 72.23
- Email: rgruel@chu-grenoble.fr
Study Locations
-
-
-
Grenoble Cedex 9, France, 38043
- Recruiting
- Chu Grenoble Alpes
-
Contact:
- GRUEL Réjane
- Phone Number: +33 (0)4 76 76 72.23
- Email: rgruel@chu-grenoble.fr
-
Contact:
- GRANGE Laurent, PH
- Phone Number: +33 (0)4 76 76 51 36
- Email: lgrange@chu-grenoble.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- If woman, not to be pregnant
- Have radiographically diagnosed osteoarthritis of the knee that meets OARSI criteria for gonarthrosis (Altman and Gold, 2007; Kellgren and Lawrence, 1957).
- Present a Kellgren-Lawrence radiographic score lower than 4
- Be treated with visco-supplementation after failure of conventional analgesic treatments and non-pharmacological modalities.
Exclusion Criteria:
- BMI greater than 28
- BMI lower than 15
- Kellgren-Lawrence score of 4
- Patients with no clinical symptoms of osteoarthritis
- Patients treated with intra-articular steroid injection during follow-up
- Patients who have had a synovectomy
- Patients with severe systemic disease or with rheumatoid arthritis or other intercurrent rheumatic disease
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Osteoarthritic patients
Subjects are patients referred for knee osteoarthritis and treated with an hyaluronic acid injection (viscosupplementation)
|
Synovial fluid is collected as part of a conventional injection of viscosupplement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarkers analysis based on Raman analysis of synovial fluid (SF) (SYNODIAG)
Time Frame: 6 months
|
Measuring the physicochemical index of the dried drop of SF (Raman ratios) between responding and non-responding patients.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: GRANGE Laurent, University Hospital, Grenoble
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 38RC17.414
- 2017-A03663-50 (Other Identifier: ID RCB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis, Knee
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Thammasat UniversityCompletedPrimary Knee OsteoarthritisThailand
-
Galderma R&DCompletedUnilateral Knee OsteoarthritisUnited Kingdom
-
National Yang Ming UniversityFar Eastern Memorial HospitalCompletedMedial Knee OsteoarthritisTaiwan
-
Hanlim Pharm. Co., Ltd.CompletedKnee OsteoarthritisKorea, Republic of
Clinical Trials on Viscosupplements
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedOsteoarthritis
-
Boehringer IngelheimCompleted
-
Sheltering Arms Physical Rehabilitation HospitalsGenzyme, a Sanofi Company; Virginia Commonwealth UniversityUnknown
-
Shafer Clinic Fifth AvenueRecruitingMicropenisUnited States
-
Damascus UniversityCompletedImplant ComplicationSyrian Arab Republic
-
Damascus UniversityCompletedPatients With Dental ExtractionSyrian Arab Republic
-
University of OxfordUnknownKnee OsteoarthritisUnited Kingdom
-
Kessler FoundationUnknown
-
TRB ChemedicaCompleted